Kun‐Chieh Chen

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Anti-cancer natural products isolated from chinese medicinal herbs

EGFR Antagonists in Cancer Treatment

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

The biology and management of non-small cell lung cancer

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Epidermal growth factor receptor mutations in lung cancer

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Endostar combined with radiotherapy increases radiation sensitivity by decreasing the expression of TGF-β1, HIF-1α and bFGF

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

Molecular targets of luteolin in cancer

RAS-targeted therapies: is the undruggable drugged?

Multimodal biomedical AI

Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives

Acne vulgaris

Drug-Induced Skin, Nail and Hair Disorders

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Deep learning in cancer pathology: a new generation of clinical biomarkers

Mechanisms of cutaneous toxicities to EGFR inhibitors

PROTAC targeted protein degraders: the past is prologue

Anti‐cancer properties of anthraquinones from rhubarb

Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

7,8‐Dihydroxy‐4‐methylcoumarin induces apoptosis of human lung adenocarcinoma cells by ROS‐independent mitochondrial pathway through partial inhibition of ERK/MAPK signaling

Flavonoids in Cancer and Apoptosis

Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma

Luteolin attenuates TGF-β1-induced epithelial–mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt–NF-κB–Snail pathway

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

Characteristics and Predictive Value of PD-L1 Status in Real-World Non–Small Cell Lung Cancer Patients

Complications of Therapy in Cancer Patients